Anti-linker antibodies: a universal key for CAR-T detection
Every new CAR-T needs a new detection tool – until now. Anti-linker antibodies could change how researchers develop and track these therapies.
List view / Grid view
Every new CAR-T needs a new detection tool – until now. Anti-linker antibodies could change how researchers develop and track these therapies.
A new research study has discovered that targeted antioxidants could restore T cell function – offering a potential boost for cancer immunotherapies like CAR-T.
Choosing the right bispecific antibody format can make or break your therapy’s success. This article explores how format impacts function, manufacturability and development strategy - helping you make the best choice from the start.
Bispecific T-cell engagers are advancing fast - but complexity still slows development. This article explores how data-driven, platform-based strategies are helping overcome design and manufacturing hurdles to bring these next-gen therapies to patients faster.
A new study from the Van Andel Institute shows that glucose not only fuels T cells but also strengthens their internal signalling and cancer-fighting capabilities –offering a potential route to improved immunotherapies.
Researchers in China have developed a next-generation CAR-T cell therapy armed with nanogels that can penetrate the dense barriers of solid tumours. This addresses a major limitation in the treatment of solid cancers with immunotherapy.
Scientists have found a key mechanism driving immune regulation in autoimmune diseases like MS and IBD – which could lead to new targeted treatments.
In the evolving landscape of cell and gene therapy, early-stage manufacturing remains a major hurdle. In this interview, Maria Knaub at Terumo Blood and Cell Technologies shares how a strategic collaboration with FUJIFILM Biosciences is streamlining T-cell expansion workflows.
A new dual CAR-T cell therapy targeting two tumour-specific proteins in T-cell Acute Lymphoblastic Leukaemia (T-ALL) has been developed – meaning effective treatment for this aggressive blood cancer could soon become a reality.
A new “leukaemia-on-a-chip” device replicates human bone marrow and immune interactions, enabling researchers to observe CAR T cell therapies in action - potentially allowing for more personalised treatment strategies for leukaemia patients.
Researchers have developed a new method to generate CAR T cells directly inside the body using targeted lipid nanoparticles that deliver mRNA to T cells - offering a safer, faster and more accessible alternative to traditional cell therapies for cancer and autoimmune diseases.
Amelie Croset of Molecular Partners breaks down the DARPin developments featured at AACR 2025 – from targeted radiopharmaceuticals to precision-engineered immune cell engagers.
A new study reveals that BCG, a decades-old bladder cancer treatment, reprograms the immune system at the bone marrow level, offering a new perspective into how this immunotherapy boosts the body’s defence against cancer.
Researchers at the University of Michigan have engineered a herpes virus protein to enhance T cell survival and function, offering a new strategy to strengthen cancer immunotherapy.
Discover how Chromatin Bioscience’s synthetic promoters are transforming gene therapy by enhancing precision, boosting safety and improving manufacturing efficiency.